DIAGENS-B (02526) saw its shares rise more than 15% during the morning session, reaching a record high of HK$335. This represents an increase of nearly 240% compared to its IPO price of HK$99. As of the time of writing, the stock was up 11.81% at HK$322, with a turnover of HK$37.38 million.

The surge follows the company's participation in the third phase of the 139th Canton Fair, which opened in Guangzhou on May 1. The event featured a dedicated Smart Healthcare zone showcasing cutting-edge technologies in the global medical health sector. DIAGENS-B presented its self-developed iMedImage® medical imaging foundation model at the fair, attracting significant attention. Its booth was crowded with buyers from regions including the Middle East, Southeast Asia, and Europe, who showed strong interest in its technology and products.

A recent analysis highlighted that DIAGENS-B's 2025 annual report serves as a powerful demonstration of its capabilities. A 332% surge in technology licensing revenue validates the feasibility of its large model commercial loop. The company maintains a dominant position in a policy-driven essential sector with a 30.6% market share. Furthermore, the endorsement of the iMedImage® foundation model by leading institutions such as Tencent underscores its strategic value as a global AI medical infrastructure service provider.